Jefferies Group Comments on Hologic, Inc.’s Q3 2018 Earnings (HOLX)
Hologic, Inc. (NASDAQ:HOLX) – Research analysts at Jefferies Group upped their Q3 2018 EPS estimates for shares of Hologic in a note issued to investors on Thursday. Jefferies Group analyst R. Denhoy now forecasts that the medical equipment provider will post earnings of $0.57 per share for the quarter, up from their previous forecast of $0.54. Jefferies Group also issued estimates for Hologic’s Q4 2018 earnings at $0.60 EPS, FY2018 earnings at $2.25 EPS, FY2019 earnings at $2.52 EPS and FY2020 earnings at $2.83 EPS.
Other research analysts have also issued research reports about the stock. Cowen upgraded shares of Hologic to a “buy” rating and set a $52.00 price target on the stock in a research note on Wednesday, December 20th. Needham & Company LLC reiterated a “buy” rating and issued a $50.00 target price (up from $48.00) on shares of Hologic in a research note on Tuesday, January 9th. Bank of America upgraded shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 target price on the stock in a research note on Thursday, January 4th. Piper Jaffray Companies reiterated a “buy” rating and issued a $48.00 target price on shares of Hologic in a research note on Thursday, November 9th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $48.00 target price on shares of Hologic in a research note on Friday. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Hologic presently has an average rating of “Buy” and a consensus target price of $48.36.
Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The company had revenue of $791.10 million for the quarter, compared to analyst estimates of $785.80 million. During the same quarter in the prior year, the business posted $0.52 EPS. Hologic’s quarterly revenue was up 7.7% on a year-over-year basis.
In other Hologic news, VP Karleen Marie Oberton sold 1,023 shares of the stock in a transaction on Monday, November 20th. The shares were sold at an average price of $39.84, for a total value of $40,756.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.88% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the company. Parnassus Investments CA lifted its holdings in shares of Hologic by 88.6% during the 4th quarter. Parnassus Investments CA now owns 14,240,875 shares of the medical equipment provider’s stock worth $608,797,000 after acquiring an additional 6,689,454 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of Hologic by 5.8% during the 4th quarter. Victory Capital Management Inc. now owns 6,199,017 shares of the medical equipment provider’s stock worth $265,008,000 after acquiring an additional 342,239 shares during the period. Pictet Asset Management Ltd. lifted its holdings in shares of Hologic by 50.3% during the 3rd quarter. Pictet Asset Management Ltd. now owns 2,912,338 shares of the medical equipment provider’s stock worth $106,854,000 after acquiring an additional 974,325 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Hologic by 5.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,969,026 shares of the medical equipment provider’s stock worth $72,243,000 after acquiring an additional 105,360 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Hologic by 3.5% during the 3rd quarter. Legal & General Group Plc now owns 1,426,469 shares of the medical equipment provider’s stock worth $52,333,000 after acquiring an additional 48,577 shares during the period. 93.84% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/jefferies-group-comments-on-hologic-inc-s-q3-2018-earnings-holx/1863333.html.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.